Microvessel density and expression of vascular endothelial growth factor in clinically localized prostate cancer

Polish Journal of Pathology

Volumn 64, Issue 1, 2013, Pages 33-38

  Łuczyńska, Elzbieta ^a   Gasińska, Anna ^a   Wilk, Wacław ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

MVD; Prostatic cancer; Vascular density; VEGF

Indexed keywords

CD34 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; VASCULOTROPIN A;

AGED; ARTICLE; BLOOD; CANCER GRADING; CARCINOMA; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MICROVASCULATURE; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; PROSTATECTOMY; TUMOR VOLUME; VASCULARIZATION;

AGED; ANTIGENS, CD34; CARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROVESSELS; MIDDLE AGED; NEOPLASM GRADING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84876966573     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: 10.5114/PJP.2013.34601     Document Type: Article

References (28)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
2. Boddy JL, Fox SB, Han C, et al. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 2005; 11: 7658-7663.
3. Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 2007; 17: 71-77.
4. Jackson MW, Roberts JS, Heckford SE, et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 2002; 62: 854-859.
5. Green MML, Hiley CT, Shanks JH, et al. Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys 2007; 67: 84-90.
6. Borre M, Nerstrom B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000; 6: 1882-1890.
7. Zeng Y, Opeskin K, Baldwin ME, et al. Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res 2004; 10: 5137-5144.
8. de la Taille A, Katz AE, Bagiella E, et al. Microvessel density as predictor of PSA recurrence after radical prostatectomy. A comparison of CD34 and CD31. Am J Clin Pathol 2000; 113: 555-562.
9. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-409.
10. Luczynska E, Gasinska A, Wilk W. Expression of Ki-67 (MIB-1) and GLUT-1 proteins in non-advanced prostatic cancer. Pol J Pathol 2012; 63: 272-277.
11. Wu T TL, Wang JS, Jiann BP, et al. Expression of vascular endothelial growth factor in Taiwanese benign and malignant prostate tissue. J Chin Med Assoc 2007: 70: 380-384.
12. Ferrer FA, Miller LJ, Andrawis RI, et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by prostate cancer cells. J Urol 1997: 157: 2329-2333.
13. Brawer MK, Deering RE, Brown M, et al. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 1994; 73: 678-687.
14. Barth PJ, Weingärtner K, Köhler HH, Bittinger A. Assessment of the vascularization in prostate carcinoma: A morphometric investigation. Hum Pathol 1996; 27: 1306-1310.
15. Borre M, Offersen BV, Nerstrm B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998; 78: 940-944.
16. Rubin MA, Buyyounouski M, Bagiella E, et al. Microvessel density in prostate cancer: lack of correlation with tumour grade, pathological stage, and clinical outcome. Urology 1999; 53: 542-547.
17. Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adeno-carcinoma of the prostate. Cancer 1997; 79: 772-779.
18. Rogatsch H, Hittmair A, Reissigl A, et al. Microvessel density in core biopsies of prostatic adenocarcinoma: a stage predictor? J Pathol 1997; 182: 205-210.
19. Bono AV, Celato N, Cova V, et al. Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 2002; 5: 123-127.
20. Erbersdobler A, Isbarn H, Dix K, et al. Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol 2010; 28: 687-692.
21. Arakawa A, Soh S, Chakraborty S, et al. Prognostic significance of angiogenesis In clinically localized prostate cancer (staining for Factor VIII-related antigen and CD34 antigen. Prostate Cancer and Prostatic Dis 1997; 1 32-38.
22. Bettencourt MC, Bauer JJ, Sesterhenn IA, et al. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 1998; 160: 459-465.
23. Mucci LA, Powolny A, Giovannucci E, et al. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 2009; 27: 5627-5633.
24. Taverna G, Grizzi F, Colombo P, Graziotti PP. Microvessel density estimate: friend or foe in the light of prostate vascular system complexity? World J Urol 2010; 28: 405-406.
25. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Nat Can Inst 2002; 94: 883-893.
26. Taverna G, Colombo P, Grizzi F, et al. Fractal analysis of twodimensional vascularity in primary prostate cancer and surrounding non-tumoral parenchyma. Pathol Res Pract 2009; 205: 438-444.
27. Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997; 3: 2507-2511.
28. Wegiel B, Evans S, Hellsten R, et al. Molecular pathways in the progression of hormone-independent and metastatic prostate cancer. Curr Can Drug Targets 2010; 10: 392-401.